Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Gilead Sciences, Inc.    GILD

GILEAD SCIENCES, INC. (GILD)

 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
05/17/2017 05/18/2017 05/19/2017 05/22/2017 05/23/2017 Date
64.51(c) 64.43(c) 64.23(c) 64.36(c) 64.69(c) Last
8 976 053 7 925 979 8 429 358 7 162 917 5 089 887 Volume
-1.84% -0.12% -0.31% +0.20% +0.51% Change
More quotes
Financials ($)
Sales 2017 24 515 M
EBIT 2017 15 036 M
Net income 2017 9 722 M
Debt 2017 4 528 M
Yield 2017 3,32%
Sales 2018 22 298 M
EBIT 2018 13 333 M
Net income 2018 8 714 M
Debt 2018 5 955 M
Yield 2018 3,58%
P/E ratio 2017 8,64
P/E ratio 2018 9,54
EV / Sales2017 3,62x
EV / Sales2018 4,04x
Capitalization 84 101 M
More Financials
Company
Gilead Sciences, Inc. is a biopharmaceutical company, which discovers, develops and commercializes therapeutics for unmet medical need.It focuses on human immunodeficiency virus and liver diseases, such as chronic hepatitis C virus infection & chronic hepatitis B virus infection, hematology &... 
More about the company
Surperformance© ratings of Gilead Sciences, Inc.
Trading Rating : Investor Rating :
More Ratings
Latest news on GILEAD SCIENCES, INC.
05/19 GILEAD SCIENCES : considers producing Hep C drug in Egypt
05/19 GILEAD SCIENCES : American “Gilead Sciences” considers producing new..
05/18 GILEAD SCIENCES, INC. (NASDAQ : GILD) Files An 8-K Submission of Matters to a Vo..
05/18 GILEAD SCIENCES : Submission of Matters to a Vote of Security Holders (form 8-K/..
05/12 GILEAD SCIENCES,INC. (NASDAQ : GILD) Files An 8-K Departure of Directors or Cert..
05/12 GILEAD SCIENCES INC : Change in Directors or Principal Officers, Submission of M..
05/11 GILEAD SCIENCES : to Present at the Bank of America Merrill Lynch Healthcare Con..
05/10 GILEAD SCIENCES : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AN..
05/09 NATCO PHARMA : launches Hepatitis C drug Velpanat in India
05/09 MEMBER SPOTLIGHT : Gilead Sciences
More news
Sector news : Bio Therapeutic Drugs
05/22 Cross-border M&A between U.S. and European firms at 10 year high
05/22DJAMGEN : Another Gloomy Day for Amgen
05/09 Sanofi pegs U.S. drug price rises to below healthcare inflation
05/09DJVERTEX PHARMACEUTICALS INCORPORATED : Trump's Pick to Lead FDA Has Backing of Bi..
05/07 REGENERON SHARES POISED FOR REBOUND : Barron's
More sector news : Bio Therapeutic Drugs
4-Traders Strategies on GILEAD SCIENCES, INC. 
2014A valuable trading opportunity
2014Continuation of the bullish trend
More Strategies
Latest Tweets
05/22Galectin Therapeutics: 1 More Shot To Get It Right? $CNAT $GILD $GALT  
05/22Galectin Therapeutics: 1 More Shot To Get It Right?
1
05/22Getting crushed again today, sold LONGS $GILD $P and $MTCH 
05/22Gilead's Dividend Stream Is Undervalued  
05/22The Sweetness of Gilead in 'The Handmaid's Tale': Sugar Is Not Salvation (@Ma.. 
More tweets
Qtime:277
News from SeekingAlpha
05/22 GALECTIN THERAPEUTICS : 1 More Shot To Get It Right?
05/22 Gilead's Dividend Stream Is Undervalued
05/22 Gilead Should Buy Incyte - Cramer's Lightning Round (5/19/17)
05/19 MONTHLY REVIEW OF DIVGRO : April 2017
05/19 Buy Gilead And Get HCV For Free
Advertisement
Chart GILEAD SCIENCES, INC.
Duration : Period :
Gilead Sciences, Inc. Technical Analysis Chart | GILD | US3755581036 | 4-Traders
Full-screen chart
Technical analysis trends GILEAD SCIENCES, ...
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 27
Average target price 78,6 $
Spread / Average Target 22%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
John F. Milligan President, Chief Executive Officer & Director
John C. Martin Executive Chairman
Kevin B. Young Chief Operating Officer
Robin L. Washington Chief Financial Officer & Executive Vice President
Norbert W. Bischofberger Chief Scientific Officer & Executive VP-Research
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
GILEAD SCIENCES, INC.-10.12%84 101
AMGEN, INC.4.66%112 531
CELGENE CORPORATION-0.03%90 349
REGENERON PHARMACEUTIC..22.59%48 999
ACTELION LTD24.04%30 824
VERTEX PHARMACEUTICALS..61.45%29 624
More Results